Jounce To Announce Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, August 9, 2017
Published: Aug 02, 2017
CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies coupled with predictive biomarkers for patient enrichment, today announced that it will report second quarter 2017 financial results on Wednesday, August 9, 2017. Jounce Therapeutics' management team will host a conference call and live audio webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please dial (833) 584-0037 (domestic) or (409) 350-3605 (international) and refer to conference ID 61078435. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s wesbite approximately two hours after the call and will be available for 30 days.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com.
Media Contact: Katie Engleman Pure Communications, Inc. (919) 333-7722 email@example.com Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 firstname.lastname@example.org